Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 3
2005 2
2006 4
2007 7
2008 6
2009 8
2010 8
2011 3
2012 3
2013 2
2014 7
2015 7
2016 8
2017 8
2018 6
2019 7
2020 12
2021 12
2022 9
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.
Korell F, Entenmann L, Romann S, Giannitsis E, Schmitt A, Müller-Tidow C, Frey N, Dreger P, Schmitt M, Lehmann LH. Korell F, et al. Among authors: schmitt a. EClinicalMedicine. 2024 Feb 27;69:102504. doi: 10.1016/j.eclinm.2024.102504. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38544797 Free PMC article.
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E, Secker KA, Nitulescu AM, Schairer R, Keppeler H, Wesle A, Schmid H, Schmitt A, Neuber B, Chmiest D, Podavini S, Märklin M, Klimovich B, Schmitt M, Korkmaz F, Lengerke C, Schneidawind C, Schneidawind D. Moraes Ribeiro E, et al. Among authors: schmitt a. J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829. J Immunother Cancer. 2024. PMID: 38296597 Free PMC article.
Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis.
Merkt W, Freitag M, Claus M, Kolb P, Falcone V, Röhrich M, Rodon L, Deicher F, Andreeva I, Tretter T, Tykocinski LO, Blank N, Watzl C, Schmitt A, Sauer T, Müller-Tidow C, Polke M, Heußel CP, Dreger P, Lorenz HM, Schmitt M. Merkt W, et al. Among authors: schmitt a. Ann Rheum Dis. 2024 Mar 12;83(4):543-546. doi: 10.1136/ard-2023-225174. Ann Rheum Dis. 2024. PMID: 38135464 Free PMC article. No abstract available.
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
Kauer J, Freundt EP, Schmitt A, Weinhold N, Mai EK, Müller-Tidow C, Goldschmidt H, Raab MS, Kriegsmann K, Sauer S. Kauer J, et al. Among authors: schmitt a. BMC Cancer. 2023 Nov 21;23(1):1132. doi: 10.1186/s12885-023-11507-9. BMC Cancer. 2023. PMID: 37990162 Free PMC article. Clinical Trial.
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.
Sauer S, Kriegsmann K, Nientiedt C, Schmitt A, Müller-Tidow C, Raab MS, Kauer J. Sauer S, et al. Among authors: schmitt a. Transfus Med Hemother. 2023 Mar 24;50(5):371-381. doi: 10.1159/000529691. eCollection 2023 Oct. Transfus Med Hemother. 2023. PMID: 37936633 Free PMC article.
117 results